In addition, we recently reported the possibility that baseline serum Ang2 levels could predict non-regression of liver fibrosis stage based on liver stiffness measurement (LSM) at 24 weeks after DAA therapy with high accuracy (sensitivity 0.882, specificity 0.733)13. This evidence concerns the gene ANGPT2 and Hepatic fibrosis.